A human MDR1 CDNA was introduced into yeast cells. Immunoblot analysis and indirect immunostainingshowedthat someof the P-glycoprotein produced was situated in its native orientation in the yeast plasma membrane.Drug-binding activities of the recombinant P-glycoproteins were markedly decreased compared to that of the authentic P-glycoprotein. To identify the bases of decreased binding westudied the effects of membrane component sterols on the azidopine binding and found that ergosterol, which is the main sterol in the yeast membrane,and calciferol, which is produced from ergosterol by UVirradiation, inhibited azidopine binding. These sterols in yeast membrane probably inhibit the function of human P-glycoprotein as a multidrug transporter in yeast cells, because expression of P-glycoprotein in yeast cells did not confer resistance to doxorubicin.
The development of multidrug resistance of tumor cells is an important clinical problem in cancer therapy. In tissue culture cells, drug resistance is associated with the expression of the MDR1gene,1'2* and the transfer ofa cloned MDR1 CDNA into drug-sensitive cells is sufficient to confer the typical multidrug resistance phenotype. 3'4) The mechanism of action of P-glycoprotein has been studied in various ways in vitro and in vivo, including transport studies,5'6) binding studies,7) and photoaffinity labeling experiments.8'9) These studies indicate that P-glyoprotein interacts directly with drugs to which cells are resistant and with agents that reverse resistance and transports them out of cells in an ATPdependent manner. Although these drugs and agents are functionally and structurally dissimilar, they appear to share one or a small number of binding sites on P-glycoprotein.
In this paper, we expressed human Pglycoprotein in yeast to develop a simple system to study its activities. HumanP-glycoprotein
To whomcorrespondence should be addressed. 1859 expressed in yeast had a markedly decreased drug-binding activity, and did not function as a drug transporter in the yeast plasma membrane.Westudied the effects of components of the plasma membrane on the activity of P-glycoprotein, and found that ergosterol, a major sterol in yeast plasma membrane, and calciferol inhibited the drug binding activity of />-APMSF.* An approximately equal volume of zirconium beads (0.5mm in diameter) were added to the cell suspension, and cells were disrupted by vigoruously shaking at 4°C for 5min. The disrupted cells were centrifuged at 120 x g at4°C for 10 min, and then the pellet was discarded. The supernatant was then centrifuged at 27,000 x g at 4°C for 10min. The fraction of the 27,000xg pellet was
Tris-HCl, pH 7.5, 0.2mM /?-APMSF). After protein was measured by the method of Bradford,13) the membrane fraction was diluted with vesicle buffer to give 2/xg of protein per /ul and stored at -70°C until analyzed.
Results

Expression of human P-glycoprotein in yeast
The humanP-glycoprotein expression vector pYMl was introduced into the yeast S. cerevisiae strain EH13-15 (a, trpl)1^using a lithium acetate method.15) Proteins in a membrane fraction prepared from yeast spheroplasts by differential centrifugation were separated by 7% SDS-polyacrylamide electrophoresis (SDS-PAGE), and blotted onto a nitrocellulose filter. The transferred proteins were reacted with the monoclonal antibody C2 1 9, which reacts with human P-glycoprotein, and then with a secondary antibody (Fig. 1A) Localization of P-glycoprotein in yeast cells P-Glycoprotein is located in the plasma membrane of human cells. The presence of P-glycoprotein in the pellet of disrupted cells (Fig. 1 ) suggested that human P-glycoprotein expressed in yeast was also present in the plasma membrane. This was confirmed by indirect immunostaining on intact spheroplasts (Fig. 2) . A strong reaction on the plasma membranewas detected after the spheroplasts of pYMltransformants incubated in the low phosphate medium were permeabilized by treatment with Triton X-100 and were incubated with the monoclonal antibody C219, followed by a secondary antibody (Fig. 2F) . Spheroplasts of pYMl transformants incubated in high phosphate mediumor of host cell alone were not stained ( Fig. 2D and B) .
(/?-Amidinophenyl)methanesulfonyl fluoride hydrochloride. The monoclonal antibody C219 has been shown to react with the cytoplasmic portion of P-glycoprotein.16) To identify the orientation of expressed human P-glycoprotein in the yeast plasma membrane, spheroplasts ofpYM1 transformants were incubated with the monoclonal antibody without permeabilization. A substantial positive reaction was observed, but i t was weaker than that produced after permeabilization (Fig. 2E) . These data suggest that a large portion of expressed human P-glycoprotein is present in the yeast plasma membrane in the correct transmembrane orientation.
Photoaffinity labeling of P-glycoprotein expressed in yeast (Fig. ID, lane 8) .
Sensitivity of yeast cells producing human P-glycoprotein to doxorubicin
It was of interest to see whether Pglycoprotein confers multidrug resistance on yeast cells, but because the yeast S. cerevisiae is rather insensitive to many lipophilic drugs, including doxorubicin and actinomycin D, we could not detect any change in drug sensitivity between the host strain EH13-15 and transformants (data not shown). We, therefore, used the doxorubicin-sensitive S. cerevisiae strain RS321 as a host cell. RS321 is a DNArepair-deficient mutant and is hypersensitive to doxorubicin.20) RS321 was transformed with the YCpvector carrying MDR1CDNAunder control of the promoter of the glycer- The doxorubicin-sensitive yeast strain RS321 (a, ade2, canl, his3, ura3, topi, rad52)20) was transformed with pYMC20 which contains MDR1 CDNA under the control of a constitutive promoter. Three ml of YNBDtop agar (0.7% agar) containing 103 to 104 yeast cells to be tested and 0 to 10fiM of doxorubicin was poured on YNBD plates containing the sameconcentration of doxorubicin.
After an incubation of3 to 5 days in the dark, the colonies were counted. #, pYMC20;O, no plasmid.
olaldehyde-3-phosphate dehydrogenase gene (GPD) and was studied for sensitivity to doxorubicin by colony formation assay (Fig.   3) . Surprisingly, yeast cells producing human P-glycoprotein were more sensitive than host cells; the LC50 of transformants and host cells were 1.2/xm and 3.1 jum, respectively. (Fig. 4) . In the presence of a 1000-fold molar excess of ergosterol (lane 7), or stigmasterol (lane 10), which is a main sterol in higher plant cells, photoaffinity labeling of P-glycoprotein was reduced, while cholesterol 1 1 Unfortunately we have not succeeded in setting up a simple system to study the activities of P-glycoprotein using the membrane fraction of yeast transformants. Our data suggest that membrane lipids could modify the activity of P-glycoprotein.
The finding that calciferol, which we take as a component of daily food, interacts with P-glycoprotein is of special interest. Calciferol might be useful to circumvent drug resistance in humans.
